title: Observation of curative efficacy and prognosis following combination chemotherapy with celecoxib in the treatment of advanced colorectal cancer.
abstract: This study investigated the antitumour and chemosensitizing effects of celecoxib in the treatment of advanced colorectal cancer. A total of 90 patients were randomly divided into two groups: group CF was treated with a combination of celecoxib and the folinic acid-fluorouracil-oxaliplatin  (FOLFOX4) regimen; and group F was treated with the FOLFOX4 regimen alone. Immunohisto chemical analysis of tumour tissues for cyclooxygenase-2 (COX-2) protein was performed. With regard to short-term efficacy, the response and disease control rates were significantly greater in group CF than  group F. A log-rank test showed that the 3-year survival rate was significantly greater in group CF than group F. It was concluded that the addition of celecoxib to the FOLFOX4 regimen increased the short-term efficacy and the 3-year survival rate, and improved the quality of life of patients  with advanced colorectal cancer. The antitumour and chemo sensitizing effects of celecoxib appeared to be independent of COX-2.
authors.affiliation: Department of Oncology, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China.
authors.forename: C-H
authors.initials: CH
authors.lastname: Jin
authors.forename: A-H
authors.initials: AH
authors.lastname: Wang
authors.forename: J-M
authors.initials: JM
authors.lastname: Chen
authors.forename: R-X
authors.initials: RX
authors.lastname: Li
authors.forename: X-M
authors.initials: XM
authors.lastname: Liu
authors.forename: G-P
authors.initials: GP
authors.lastname: Wang
authors.forename: L-Q
authors.initials: LQ
authors.lastname: Xing
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D000068579:Celecoxib; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology*; D051546:Cyclooxygenase 2 / Q000378:metabolism; D003710:Demography; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D002955:Leucovorin / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009944:Organoplatinum Compounds / Q000009:adverse effects / Q000627:therapeutic use; D000077150:Oxaliplatin; D011379:Prognosis; D011720:Pyrazoles / Q000009:adverse effects / Q000627:therapeutic use*; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D011720:Pyrazoles; D013449:Sulfonamides; D000077150:Oxaliplatin; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D000068579:Celecoxib; D002955:Leucovorin; D005472:Fluorouracil